BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 24507814)

  • 21. Refractory anemia with ring sideroblasts associated with marked thrombocytosis: a mixed group exhibiting a spectrum of morphologic findings.
    Gurevich I; Luthra R; Konoplev SN; Yin CC; Medeiros LJ; Lin P
    Am J Clin Pathol; 2011 Mar; 135(3):398-403. PubMed ID: 21350094
    [TBL] [Abstract][Full Text] [Related]  

  • 22. SF3B1 Mutation but Not Ring Sideroblasts Identifies a Specific Group of Myelodysplastic Syndrome-Refractory Cytopenia With Multilineage Dysplasia.
    Xiong B; Xue M; Yu Y; Wu S; Zuo X
    Clin Lymphoma Myeloma Leuk; 2020 May; 20(5):329-339.e3. PubMed ID: 32037286
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms.
    Malcovati L; Papaemmanuil E; Bowen DT; Boultwood J; Della Porta MG; Pascutto C; Travaglino E; Groves MJ; Godfrey AL; Ambaglio I; Gallì A; Da Vià MC; Conte S; Tauro S; Keenan N; Hyslop A; Hinton J; Mudie LJ; Wainscoat JS; Futreal PA; Stratton MR; Campbell PJ; Hellström-Lindberg E; Cazzola M;
    Blood; 2011 Dec; 118(24):6239-46. PubMed ID: 21998214
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Distinct iron architecture in SF3B1-mutant myelodysplastic syndrome patients is linked to an SLC25A37 splice variant with a retained intron.
    Visconte V; Avishai N; Mahfouz R; Tabarroki A; Cowen J; Sharghi-Moshtaghin R; Hitomi M; Rogers HJ; Hasrouni E; Phillips J; Sekeres MA; Heuer AH; Saunthararajah Y; Barnard J; Tiu RV
    Leukemia; 2015 Jan; 29(1):188-95. PubMed ID: 24854990
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Myelodysplastic syndromes with ring sideroblasts (MDS-RS) and MDS/myeloproliferative neoplasm with RS and thrombocytosis (MDS/MPN-RS-T) - "2021 update on diagnosis, risk-stratification, and management".
    Patnaik MM; Tefferi A
    Am J Hematol; 2021 Mar; 96(3):379-394. PubMed ID: 33428785
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Refractory anemia with ringed sideroblasts and thrombocytosis without JAK2 V617F mutation: report of three cases.
    Tatic A; Vasilică M; Coliţă A; Vasilache D; Dobrea C; Jardan C; Găman AM; Crişan AM; Coliţă D; Coriu D
    Rom J Morphol Embryol; 2013; 54(4):1177-82. PubMed ID: 24399021
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Refractory cytopenia with multilineage dysplasia: further characterization of an 'unclassifiable' myelodysplastic syndrome.
    Rosati S; Mick R; Xu F; Stonys E; Le Beau MM; Larson R; Vardiman JW
    Leukemia; 1996 Jan; 10(1):20-6. PubMed ID: 8558932
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Refractory anemia with ring sideroblasts and marked thrombocytosis cases harbor mutations in SF3B1 or other spliceosome genes accompanied by JAK2V617F and ASXL1 mutations.
    Jeromin S; Haferlach T; Weissmann S; Meggendorfer M; Eder C; Nadarajah N; Alpermann T; Kohlmann A; Kern W; Haferlach C; Schnittger S
    Haematologica; 2015 Apr; 100(4):e125-7. PubMed ID: 25527566
    [No Abstract]   [Full Text] [Related]  

  • 29. JAK2/CALR/SF3B1 triple-mutated myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis evolving to myelofibrosis and SF3B1 single-mutated acute myeloid leukemia: Evidence of a pre-JAK2 clone.
    Yasuda H; Morishita S; Mori Y; Tsukune Y; Inano T; Harada S; Komatsu N
    Leuk Res; 2021 Jan; 100():106496. PubMed ID: 33373831
    [No Abstract]   [Full Text] [Related]  

  • 30. Clinical features and course of refractory anemia with ring sideroblasts associated with marked thrombocytosis.
    Broseus J; Florensa L; Zipperer E; Schnittger S; Malcovati L; Richebourg S; Lippert E; Cermak J; Evans J; Mounier M; Raya JM; Bailly F; Gattermann N; Haferlach T; Garand R; Allou K; Besses C; Germing U; Haferlach C; Travaglino E; Luno E; Pinan MA; Arenillas L; Rozman M; Perez Sirvent ML; Favre B; Guy J; Alonso E; Ahwij N; Jerez A; Hermouet S; Maynadié M; Cazzola M; Girodon F
    Haematologica; 2012 Jul; 97(7):1036-41. PubMed ID: 22532522
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MDS/MPN-RS-T justified inclusion as a unique disease entity?
    Montalban-Bravo G; Garcia-Manero G
    Best Pract Res Clin Haematol; 2020 Jun; 33(2):101147. PubMed ID: 32460979
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis: Ringing in a new future.
    Nathan DI; Feld J; El Jamal SM; Mascarenhas J; Tremblay D
    Leuk Res; 2022 Apr; 115():106820. PubMed ID: 35279478
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical importance of SF3B1 mutations in Chinese with myelodysplastic syndromes with ring sideroblasts.
    Cui R; Gale RP; Xu Z; Qin T; Fang L; Zhang H; Pan L; Zhang Y; Xiao Z
    Leuk Res; 2012 Nov; 36(11):1428-33. PubMed ID: 22921018
    [TBL] [Abstract][Full Text] [Related]  

  • 34. SF3B1, a splicing factor is frequently mutated in refractory anemia with ring sideroblasts.
    Visconte V; Makishima H; Jankowska A; Szpurka H; Traina F; Jerez A; O'Keefe C; Rogers HJ; Sekeres MA; Maciejewski JP; Tiu RV
    Leukemia; 2012 Mar; 26(3):542-5. PubMed ID: 21886174
    [No Abstract]   [Full Text] [Related]  

  • 35. Clinical Application for Diagnosis of Myelodysplatic/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis.
    Lee MY; Jang S; Park CJ; Cho YU
    Clin Lab; 2022 Apr; 68(4):. PubMed ID: 35443589
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia.
    Malcovati L; Papaemmanuil E; Ambaglio I; Elena C; Gallì A; Della Porta MG; Travaglino E; Pietra D; Pascutto C; Ubezio M; Bono E; Da Vià MC; Brisci A; Bruno F; Cremonesi L; Ferrari M; Boveri E; Invernizzi R; Campbell PJ; Cazzola M
    Blood; 2014 Aug; 124(9):1513-21. PubMed ID: 24970933
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Gene mutation and myelodysplastic syndromes with ring sideroblast excess].
    Meng FK; Huang LF; Zhou JF; Sun HY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Aug; 21(4):1088-90. PubMed ID: 23998618
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Disruption of SF3B1 results in deregulated expression and splicing of key genes and pathways in myelodysplastic syndrome hematopoietic stem and progenitor cells.
    Dolatshad H; Pellagatti A; Fernandez-Mercado M; Yip BH; Malcovati L; Attwood M; Przychodzen B; Sahgal N; Kanapin AA; Lockstone H; Scifo L; Vandenberghe P; Papaemmanuil E; Smith CW; Campbell PJ; Ogawa S; Maciejewski JP; Cazzola M; Savage KI; Boultwood J
    Leukemia; 2015 May; 29(5):1092-103. PubMed ID: 25428262
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development of refractory anemia with ring sideroblasts associated with thrombocytosis from pre-existing refractory anemia with ring sideroblasts through acquisition of Jak2 V617F mutation.
    Lu CM; Zhou L; Wang E; Feng S; Sebastian S; Behler C
    Leuk Lymphoma; 2011 Dec; 52(12):2405-7. PubMed ID: 21806348
    [No Abstract]   [Full Text] [Related]  

  • 40. Myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T): Mayo-Moffitt collaborative study of 158 patients.
    Mangaonkar AA; Lasho TL; Ketterling RP; Reichard KK; Gangat N; Al-Kali A; Begna KH; Pardanani A; Al Ali NH; Talati C; Sallman D; Padron E; Patnaik MM; Tefferi A; Komrokji R
    Blood Cancer J; 2022 Feb; 12(2):26. PubMed ID: 35105856
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.